The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.